Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06515613 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
A Phase 1 study of Endometrial Cancer and Platinum-resistant Ovarian Cancer, sponsored by Context Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 80
- Enrollment target
- 13
- Study locations
NCT06515613: Recruiting Phase 1 study of Endometrial Cancer and Platinum-resistant Ovarian Cancer, sponsored by Context Therapeutics.
NCT06515613 is a Phase 1 study of Endometrial Cancer and Platinum-resistant Ovarian Cancer that is actively recruiting participants, run by Context Therapeutics. The registered enrollment target is 80 participants, below the 524-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (85% lower). The trial reports 13 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06515613, a Phase 1 study of Endometrial Cancer and Platinum-resistant Ovarian Cancer, is actively recruiting participants, sponsored by Context Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 80 participants
- Enrollment target
- 13
- Study locations
Study Summary
This is a Phase 1a/1b, open-label, dose escalation and expansion study to evaluate the safety and efficacy of CTIM-76 (study drug), a CLDN6-directed T cell-engaging bispecific antibody, in participants with platinum-refractory/resistant ovarian cancer (PRROC) and other advanced CLDN6-positive solid tumors (i.e., testicular and endometrial).
Primary Outcome
Phase 1a will evaluate increasing doses of CTIM-76 based on the assessment of DLTs
Conditions Studied
Interventions
- DRUG CTIM-76
Study Locations (13)
Arkansas
- University of Arkansas Winthrop P. Rockefeller Cancer Institute - Little Rock
California
- Precision NextGen Oncology & Research Center - Beverly Hills
Colorado
- SCRI at Denver Health - Denver
Massachusetts
- Dana-Farber Cancer Institute - Boston
New Jersey
- John Theurer Cancer Center - Hackensack
New York
- Memorial Sloan Kettering Cancer Center - New York
North Carolina
- Duke Cancer Institute - Durham
Ohio
- Gabrail Cancer Center - Canton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2024-07-10 |
| Est. Completion | 2028-04-30 |
| Phase | Phase 1 |
What NCT06515613 shows while recruiting
NCT06515613 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 524-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (85% lower).
The record links to 3 conditions, with Endometrial Cancer appearing as the primary indexed condition, and to 1 intervention - of which CTIM-76 is the first listed.
NCT06515613 lists 13 locations in 13 states (Arkansas, California, Colorado).
Frequently Asked Questions
What is clinical trial NCT06515613 about?
NCT06515613 is a clinical study titled "A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors". This is a Phase 1a/1b, open-label, dose escalation and expansion study to evaluate the safety and efficacy of CTIM-76 (study drug), a CLDN6-directed T cell-engaging bispecific antibody, in participants with platinum-refractory/resistant ovarian cancer (PRROC) and other advanced CLDN6-positive solid ...
What is the current status of trial NCT06515613?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2024-07-10. Estimated completion is 2028-04-30.
What conditions does trial NCT06515613 study?
This clinical trial studies the following conditions: Endometrial Cancer, Platinum-resistant Ovarian Cancer, Testicular Cancer.
What interventions are being tested in trial NCT06515613?
The interventions under investigation include: CTIM-76 (DRUG).
Who is sponsoring clinical trial NCT06515613?
This trial is sponsored by Context Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06515613 being conducted?
This trial has 13 study locations across Arkansas, California, Colorado, Massachusetts, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endometrial Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06515613's enrollment target sits among peer trials
80 102nd of 181 higher than 80 of 181 other Endometrial Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Endometrial Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
RECRUITING · Phase 1
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
RECRUITING · Phase 1
-
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI